Clinical Trial Update: Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Velcade (bortezomib) plus high-dose dexamethasone in newly diagnosed multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Velcade (bortezomib)

Snippet

Sponsor: Nantes University Hospital | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED